Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 1, 2017, Pages 132-136

  Wang, Cheng ^a,b   Ji, Dong ^c   Chen, Jing ^a   Shao, Qing ^c   Li, Bing ^c   Liu, Jialiang ^c   Wu, Vanessa ^a   Wong, April ^a   Wang, Yudong ^a   Zhang, Xiaoyong ^b   Lu, Lei ^a   Wong, Chris ^d   Tsang, Stella ^d   Zhang, Zheng ^c   Sun, Jian ^b   Hou, Jinlin ^b   Chen, Guofeng ^c   Lau, George ^a,c  

^a Humanity and Health Clinic   (Hong Kong)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c BEIJING 302 HOSPITAL   (China)

^d Hong Kong Molecular Pathology Diagnostic Centre   (Hong Kong)

Author keywords

Coinfection; Prognostic Factor; Risk Factor; Therapy

Indexed keywords

DACLATASVIR; DACLATASVIR PLUS SOFOSBUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; HEPATITIS B SURFACE ANTIGEN; LEDIPASVIR PLUS SOFOSBUVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHINA; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B VIRUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBSERVATIONAL STUDY; POPULATION RESEARCH; PROSPECTIVE STUDY; RISK FACTOR; VIRUS REACTIVATION; BLOOD; COMPLICATION; ENDEMIC DISEASE; HEPATITIS B; HEPATITIS C, CHRONIC; MIDDLE AGED; VERY ELDERLY; VIRUS ACTIVATION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHINA; DNA, VIRAL; ENDEMIC DISEASES; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 85002245074     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.06.023     Document Type: Article

References (20)

1. 1 Amin, J., Law, M.G., Bartlett, M., et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 368 (2006), 938–945.
2. 2 Yu, G., Chi, X., Wu, R., et al. Replication inhibition of hepatitis B virus and hepatitis C virus in co-infected patients in Chinese population. PLoS One, 10, 2015, e0139015.
3. 3 Sagnelli, E., Coppola, N., Messina, V., et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 36 (2002), 1285–1291.
4. 4 Fukuda, R., Ishimura, N., Niigaki, M., et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 58 (1999), 201–207.
5. 5 Pollicino, T., Squadrito, G., Cerenzia, G., et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126 (2004), 102–110.
6. 6 Ende, A.R., Kim, N.H., Yeh, M.M., et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep, 9, 2015, 164.
7. 7 Takayama, H., Sato, T., Ikeda, F., et al. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with HBV/HCV co-infection. Hepatol Res 46 (2015), 489–491.
8. 8 Collins, J.M., Raphael, K.L., Terry, C., et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 61 (2015), 1302–1306.
9. 9 De Monte, A., Courjon, J., Anty, R., et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol 78 (2016), 27–30.
10. 10 EMA reviews direct-acting antivirals for hepatitis C. 2016. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Direct-acting_antivirals_indicated_for_treatment_of_hepatitis_C_(interferon-free)/human_referral_prac_000057.jsp&mid=WC0b01ac05805c516f. Accessed April 20, 2016.
11. 11 Liaw, Y.F., Tsai, S.L., Chang, J.J., et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 106 (1994), 1048–1053.
12. 12 Liaw, Y.F., Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J Gastroenterol 37:Suppl 13 (2002), 65–68.
13. 13 Yang, D., Zuo, C., Wang, X., et al. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc Natl Acad Sci U S A 111 (2014), E1264–E1273.
14. 14 Wiegand, S.B., Jaroszewicz, J., Potthoff, A., et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-gamma-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect, 21, 2015 710 e1–e9.
15. 15 Meissner, E.G., Wu, D., Osinusi, A., et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 124 (2014), 3352–3363.
16. 16 Serti, E., Chepa-Lotrea, X., Kim, Y.J., et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 149 (2015), 190–200.
17. 17 Lau, G.K., Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2 (2008), 152–162.
18. 18 Hui, C.K., Cheung, W.W., Zhang, H.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131 (2006), 59–68.
19. 19 Horner, S.M., Gale, M. Jr., Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 19 (2013), 879–888.
20. 20 Loomba, R., Rowley, A., Wesley, R., et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148 (2008), 519–552.